

Cardiac Biomarkers Market - Global Outlook & Forecast 2023-2028

Market Report | 2023-10-20 | 305 pages | Arizton Advisory & Intelligence

AVAILABLE LICENSES:

- Single User License \$4200.00
- Team License \$4999.00
- Enterprisewide \$5999.00

Report description:

The global cardiac biomarkers market is expected to grow at a CAGR of 12.14% from 2022-2028.

MARKET TRENDS & DRIVERS

Integration of Multiple Cardiac Biomarkers

Healthcare professionals increasingly recognize the value of combining information from various biomarkers to comprehensively understand a patient's cardiac health. This approach allows for more accurate risk assessment, early detection of cardiovascular diseases, and personalized treatment strategies. By analyzing multiple biomarkers simultaneously, clinicians can provide more tailored care and improve patient outcomes in a field where precision and timely intervention are crucial.

Increasing R&D Activities of Novel Cardiac Biomarkers

The cardiac biomarkers market is witnessing a significant trend of increasing research and development (R&D) activities focused on novel cardiac biomarkers. Researchers and companies are exploring innovative molecular indicators to enhance diagnostic accuracy, risk assessment, and personalized treatment strategies for cardiovascular diseases. This trend reflects a growing commitment to advancing cardiac diagnostics, leading to the discovery of new biomarkers that can provide deeper insights into heart health, enabling early detection and improved patient outcomes.

Growing Prevalence of Cardiovascular Diseases

The escalating prevalence of CVDs is a significant driving force for the cardiac biomarkers market. With CVDs becoming a leading cause of global mortality, there's a heightened need for accurate and timely diagnosis. Cardiac biomarkers offer critical insights into heart health, enabling early detection, precise risk assessment, and effective monitoring. As the burden of CVDs continues to rise, the demand for biomarker-based diagnostic tools is growing, facilitating proactive healthcare interventions and ultimately

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott-international.com

www.scott-international.com

contributing to improved patient outcomes.

Increasing Demand for Point-of-care Cardiac Diagnostics

The cardiac biomarkers market is witnessing a surge in demand due to the increasing recognition of the value of point-of-care cardiac diagnostics. Healthcare providers are embracing rapid and convenient testing methods that offer real-time cardiac insights at the patient's bedside or in emergency settings. This trend is driven by the need for timely diagnosis and treatment of cardiovascular diseases, enhancing patient outcomes. The convenience and speed of point-of-care testing are reshaping the market, allowing for quicker interventions, risk assessment, and treatment monitoring, ultimately improving heart health management on a global scale.

SEGMENTATION INSIGHTS

INSIGHTS BY BIOMARKERS TYPE

The global cardiac biomarkers market by biomarkers type can be classified as troponin, creatine kinase (CK-MB), myoglobin, and others. The troponin segment accounted for the most significant industry share in 2022. Troponins are a group of cardiac biomarkers that have revolutionized diagnosing and managing CVDs. They are specific proteins found in cardiac muscle cells and are released into the bloodstream when there is damage to the heart muscle. Troponin biomarkers are pivotal in identifying cardiac conditions, assessing the severity of cardiac events, guiding treatment decisions, and predicting patient outcomes. Further, high-sensitivity troponin assays enhance this early detection capability, identifying tiny amounts of troponin in the blood, even without clinical symptoms.

Segmentation by Biomarkers Type

- Troponin
- Creatine Kinase (CK-MB)
- Myoglobin
- Other

INSIGHTS BY APPLICATION

The acute coronary syndrome (ACS) application segment accounted for the most significant global cardiac biomarkers market share in 2022. Acute coronary syndrome (ACS) encompasses a spectrum of clinical conditions caused by a sudden reduction or cessation of blood flow to the heart muscle due to atherosclerotic plaque rupture or erosion. Timely and accurate diagnosis of ACS is critical for guiding appropriate management and reducing morbidity and mortality. Cardiac biomarkers play a pivotal role in the assessment of ACS, aiding in the identification, risk stratification, and treatment of patients with this life-threatening condition. Cardiac biomarkers not only assist in diagnosing ACS and risk stratification but also play a role in guiding treatment decisions. Elevated cardiac biomarkers indicate myocardial injury, emphasizing the need for immediate antiplatelet therapy, such as aspirin or P2Y12 inhibitors, to prevent further clot formation.

Segmentation by Application

- Acute Coronary Syndrome
- Myocardial Infarction
- Congestive Heart Failure
- Others

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

INSIGHTS BY END-USER

The global cardiac biomarkers market by end-user is segmented into hospitals, diagnostic laboratories, and others. In 2022, hospitals accounted for a significant share of the end-user segment. Hospitals serve as vital end-users of cardiac biomarkers, utilizing them in various aspects of patient care related to cardiovascular diseases. From the emergency department to inpatient settings, cardiac biomarkers are pivotal in diagnosing acute cardiovascular events, risk-stratifying patients, and guiding treatment decisions. These biomarkers' availability and accurate interpretation enable healthcare professionals to provide timely interventions and improve patient outcomes. By leveraging the power of cardiac biomarkers, hospitals can continue to make significant strides in improving the care and outcomes of patients with cardiovascular conditions.

Segmentation by End-user

- Hospitals
- Diagnostic Laboratories
- Other

GEOGRAPHICAL ANALYSIS

North America held the most prominent global cardiac biomarkers market share in 2022. The region's leadership is attributed to factors such as the high prevalence of CVDs, a well-established healthcare infrastructure, and robust research and development activities. The U.S. and Canada are the primary contributors to the market's growth in this region, with a focus on introducing innovative biomarkers and diagnostic technologies. Moreover, increasing awareness about early disease detection and prevention drives the adoption of cardiac biomarkers in clinical practice.

Segmentation by Geography

- North America
 - o□The U.S.
 - o□Canada
- Europe
 - o□Germany
 - o□France
 - o□The U.K.
 - o□Italy
 - o□Spain
- APAC
 - o□Japan
 - o□China
 - o□India
 - o□South Korea
 - o□Australia
- Latin America
 - o□Brazil
 - o□Mexico
 - o□Argentina
- Middle East & Africa

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- o Turkey
- o South Africa
- o Saudi Arabia

VENDOR LANDSCAPE

The field of cardiac biomarkers has experienced significant growth and innovation over the past few decades, playing a pivotal role in diagnosing, prognosis, and managing CVDs. As one of the most critical segments within the broader healthcare industry, the global cardiac biomarkers market has become a competition hub, driven by the increasing prevalence of CVDs, advancements in diagnostic technologies, and the pursuit of improved patient outcomes. Furthermore, the cardiac biomarkers market is characterized by various players, including pharmaceutical companies, diagnostic manufacturers, biotechnology firms, and research institutions.

Key Company Profiles

- Abbott
- Bio-Rad Laboratories
- Danaher
- F.Hoffmann-La Roche
- PerkinElmer
- Siemens Healthineers

Other Prominent Vendors

- Abcam
- bioMerieux
- BioSupply
- BTNX
- CardioGenics
- Creative Diagnostics
- DiaSorin
- Life Diagnostics
- LumiraDx
- Medix Biochemica
- MESO SCALE DIAGNOSTICS
- MP Biomedicals
- Quidel
- Randox Laboratories
- Response Biomedical
- Tosoh

KEY QUESTIONS ANSWERED:

1. How big is the global cardiac biomarkers market?
2. What is the projected growth rate of the global cardiac biomarkers market?
3. What are the rising trends in the cardiac biomarkers market?
4. Which region holds the most significant global cardiac biomarkers market share?

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5. Who are the key players in the global cardiac biomarkers market?

Table of Contents:

1 RESEARCH METHODOLOGY

2 RESEARCH OBJECTIVES

3 RESEARCH PROCESS

4 SCOPE & COVERAGE

4.1 MARKET DEFINITION

4.1.1 INCLUSIONS

4.1.2 EXCLUSIONS

4.1.3 MARKET ESTIMATION CAVEATS

4.2 BASE YEAR

4.3 SCOPE OF THE STUDY

4.3.1 MARKET SEGMENTATION BY BIOMARKERS TYPE

4.3.2 MARKET SEGMENTATION BY APPLICATION

4.3.3 MARKET SEGMENTATION BY END-USER

4.3.4 MARKET SEGMENTATION BY GEOGRAPHY

5 REPORT ASSUMPTIONS & CAVEATS

5.1 KEY CAVEATS

5.2 CURRENCY CONVERSION

5.3 MARKET DERIVATION

6 MARKET AT A GLANCE

7 PREMIUM INSIGHTS

7.1 OVERVIEW

7.1.1 GEOGRAPHY INSIGHTS

7.1.2 BIOMARKERS TYPE INSIGHTS

7.1.3 APPLICATION INSIGHTS

7.1.4 END-USER INSIGHTS

8 INTRODUCTION

8.1 OVERVIEW

9 MARKET OPPORTUNITIES & TRENDS

9.1 DEVELOPMENT OF HIGHLY SENSITIVE BIOMARKERS FOR RISK STRATIFICATION

9.2 INTEGRATION OF MULTIPLE CARDIAC BIOMARKERS

9.3 INCREASING R&D ACTIVITIES OF NOVEL CARDIAC BIOMARKERS

10 MARKET GROWTH ENABLERS

10.1 GROWING PREVALENCE OF CARDIOVASCULAR DISEASES

10.2 INCREASING DEMAND FOR POINT-OF-CARE CARDIAC DIAGNOSTICS

10.3 ADVANCES IN CARDIAC BIOMARKERS

11 MARKET RESTRAINTS

11.1 LACK OF SPECIFICITY OF CARDIAC BIOMARKERS

11.2 AVAILABILITY OF NON-LABORATORY TESTS & GENERAL TESTS

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.3 FALSE DISCOVERIES IN CARDIAC BIOMARKERS RESEARCH

12 MARKET LANDSCAPE

12.1 MARKET OVERVIEW

12.2 MARKET SIZE & FORECAST

12.3 MARKET OPPORTUNITY

12.3.1 MARKET BY GEOGRAPHY

12.3.2 MARKET BY BIOMARKERS TYPE

12.3.3 MARKET BY APPLICATION

12.3.4 MARKET BY END-USER

12.4 FIVE FORCES ANALYSIS

12.4.1 THREAT OF NEW ENTRANTS

12.4.2 BARGAINING POWER OF SUPPLIERS

12.4.3 BARGAINING POWER OF BUYERS

12.4.4 THREAT OF SUBSTITUTES

12.4.5 COMPETITIVE RIVALRY

13 BIOMARKERS TYPE

13.1 MARKET SNAPSHOT & GROWTH ENGINE

13.2 MARKET OVERVIEW

13.3 TROPONIN

13.3.1 MARKET OVERVIEW

13.3.2 MARKET SIZE & FORECAST

13.3.3 TROPONIN MARKET BY GEOGRAPHY

13.4 CREATINE KINASE (CK-MB)

13.4.1 MARKET OVERVIEW

13.4.2 MARKET SIZE & FORECAST

13.4.3 CREATINE KINASE (CK-MB) MARKET BY GEOGRAPHY

13.5 MYOGLOBIN

13.5.1 MARKET OVERVIEW

13.5.2 MARKET SIZE & FORECAST

13.5.3 MYOGLOBIN MARKET BY GEOGRAPHY

13.6 OTHER

13.6.1 MARKET OVERVIEW

13.6.2 MARKET SIZE & FORECAST

13.6.3 OTHER MARKET BY GEOGRAPHY

14 APPLICATION

14.1 MARKET SNAPSHOT & GROWTH ENGINE

14.2 MARKET OVERVIEW

14.1 ACUTE CORONARY SYNDROME

14.1.1 MARKET OVERVIEW

14.1.2 MARKET SIZE & FORECAST

14.1.3 ACUTE CORONARY SYNDROME MARKET BY GEOGRAPHY

14.2 MYOCARDIAL INFRACTION

14.2.1 MARKET OVERVIEW

14.2.2 MARKET SIZE & FORECAST

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.2.3 MYOCARDIAL INFRACTION MARKET BY GEOGRAPHY
- 14.3 CONGESTIVE HEART FAILURE
 - 14.3.1 MARKET OVERVIEW
 - 14.3.2 MARKET SIZE & FORECAST
 - 14.3.3 CONGESTIVE HEART FAILURE MARKET BY GEOGRAPHY
- 14.4 OTHER
 - 14.4.1 MARKET OVERVIEW
 - 14.4.2 MARKET SIZE & FORECAST
 - 14.4.3 OTHER MARKET BY GEOGRAPHY

- 15 END-USER
 - 15.1 MARKET SNAPSHOT & GROWTH ENGINE
 - 15.2 MARKET OVERVIEW
 - 15.3 HOSPITALS
 - 15.3.1 MARKET OVERVIEW
 - 15.3.2 MARKET SIZE & FORECAST
 - 15.3.3 HOSPITALS MARKET BY GEOGRAPHY
 - 15.4 DIAGNOSTIC LABORATORIES
 - 15.4.1 MARKET OVERVIEW
 - 15.4.2 MARKET SIZE & FORECAST
 - 15.4.3 DIAGNOSTIC LABORATORIES MARKET BY GEOGRAPHY
 - 15.5 OTHER
 - 15.5.1 MARKET OVERVIEW
 - 15.5.2 MARKET SIZE & FORECAST
 - 15.5.3 OTHER MARKET BY GEOGRAPHY

- 16 GEOGRAPHY
 - 16.1 MARKET SNAPSHOT & GROWTH ENGINE
 - 16.2 GEOGRAPHIC OVERVIEW

- 17 NORTH AMERICA
 - 17.1 MARKET OVERVIEW
 - 17.2 MARKET SIZE & FORECAST
 - 17.2.1 NORTH AMERICA MARKET BY BIOMARKER TYPE
 - 17.2.2 NORTH AMERICA MARKET BY APPLICATION
 - 17.2.3 NORTH AMERICA MARKET BY END-USER
 - 17.3 KEY COUNTRIES
 - 17.4 US
 - 17.4.1 MARKET SIZE & FORECAST
 - 17.5 CANADA
 - 17.5.1 MARKET SIZE & FORECAST

- 18 EUROPE
 - 18.1 MARKET OVERVIEW
 - 18.2 MARKET SIZE & FORECAST
 - 18.2.1 EUROPE MARKET BY BIOMARKER TYPE
 - 18.2.2 EUROPE MARKET BY APPLICATION

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

18.2.3 EUROPE MARKET BY END-USER

18.3 KEY COUNTRIES

18.4 GERMANY

18.4.1 MARKET SIZE & FORECAST

18.5 FRANCE

18.5.1 MARKET SIZE & FORECAST

18.6 UK

18.6.1 MARKET SIZE & FORECAST

18.7 ITALY

18.7.1 MARKET SIZE & FORECAST

18.8 SPAIN

18.8.1 MARKET SIZE & FORECAST

19 APAC

19.1 MARKET OVERVIEW

19.2 MARKET SIZE & FORECAST

19.2.1 APAC MARKET BY BIOMARKER TYPE

19.2.2 APAC MARKET BY APPLICATION

19.2.3 APAC MARKET BY END-USER

19.3 KEY COUNTRIES

19.4 JAPAN

19.4.1 MARKET SIZE & FORECAST

19.5 CHINA

19.5.1 MARKET SIZE & FORECAST

19.6 INDIA

19.6.1 MARKET SIZE & FORECAST

19.7 SOUTH KOREA

19.7.1 MARKET SIZE & FORECAST

19.8 AUSTRALIA

19.8.1 MARKET SIZE & FORECAST

20 LATIN AMERICA

20.1 MARKET OVERVIEW

20.2 MARKET SIZE & FORECAST

20.2.1 LATIN AMERICA MARKET BY BIOMARKER TYPE

20.2.2 LATIN AMERICA MARKET BY APPLICATION

20.2.3 LATIN AMERICA MARKET BY END-USER

20.3 KEY COUNTRIES

20.4 BRAZIL

20.4.1 MARKET SIZE & FORECAST

20.5 MEXICO

20.5.1 MARKET SIZE & FORECAST

20.6 ARGENTINA

20.6.1 MARKET SIZE & FORECAST

21 MIDDLE EAST & AFRICA

21.1 MARKET OVERVIEW

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 21.2 MARKET SIZE & FORECAST
 - 21.2.1 MIDDLE EAST & AFRICA MARKET BY BIOMARKER TYPE
 - 21.2.2 MIDDLE EAST & AFRICA MARKET BY APPLICATION
 - 21.2.3 MIDDLE EAST & AFRICA MARKET BY END-USER
- 21.3 KEY COUNTRIES
- 21.4 TURKEY
 - 21.4.1 MARKET SIZE & FORECAST
- 21.5 SOUTH AFRICA
 - 21.5.1 MARKET SIZE & FORECAST
- 21.6 SAUDI ARABIA
 - 21.6.1 MARKET SIZE & FORECAST

- 22 COMPETITIVE LANDSCAPE
 - 22.1 COMPETITION OVERVIEW
 - 22.2 MARKET SHARE ANALYSIS
 - 22.2.1 ABBOTT
 - 22.2.2 BIO-RAD LABORATORIES
 - 22.2.3 DANAHER
 - 22.2.4 F. HOFFMANN-LA ROCHE
 - 22.2.5 PERKINELMER
 - 22.2.6 SIEMENS HEALTHINEERS

- 23 KEY COMPANY PROFILES
 - 23.1 ABBOTT
 - 23.1.1 BUSINESS OVERVIEW
 - 23.1.2 PRODUCT OFFERINGS
 - 23.1.3 KEY STRATEGIES
 - 23.1.4 KEY STRENGTHS
 - 23.1.5 KEY OPPORTUNITIES
 - 23.2 BIO-RAD LABORATORIES
 - 23.2.1 BUSINESS OVERVIEW
 - 23.2.2 PRODUCT OFFERINGS
 - 23.2.3 KEY STRATEGIES
 - 23.2.4 KEY STRENGTHS
 - 23.2.5 KEY OPPORTUNITIES
 - 23.3 DANAHER
 - 23.3.1 BUSINESS OVERVIEW
 - 23.3.2 PRODUCT OFFERINGS
 - 23.3.3 KEY STRATEGIES
 - 23.3.4 KEY STRENGTHS
 - 23.3.5 KEY OPPORTUNITIES
 - 23.4 F. HOFFMANN-LA ROCHE
 - 23.4.1 BUSINESS OVERVIEW
 - 23.4.2 PRODUCT OFFERINGS
 - 23.4.3 KEY STRATEGIES
 - 23.4.4 KEY STRENGTHS
 - 23.4.5 KEY OPPORTUNITIES

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 23.5 PERKINELMER
 - 23.5.1 BUSINESS OVERVIEW
 - 23.5.2 PRODUCT OFFERINGS
 - 23.5.3 KEY STRATEGIES
 - 23.5.4 KEY STRENGTHS
 - 23.5.5 KEY OPPORTUNITIES
- 23.6 SIEMENS HEALTHINEERS
 - 23.6.1 BUSINESS OVERVIEW
 - 23.6.2 PRODUCT OFFERINGS
 - 23.6.3 KEY STRATEGIES
 - 23.6.4 KEY STRENGTHS
 - 23.6.5 KEY OPPORTUNITIES

24 OTHER PROMINENT VENDORS

- 24.1 ABCAM
 - 24.1.1 BUSINESS OVERVIEW
 - 24.1.2 PRODUCT OFFERINGS
- 24.2 BIOMERIEUX
 - 24.2.1 BUSINESS OVERVIEW
 - 24.2.2 PRODUCT OFFERINGS
- 24.3 BIOSUPPLY
 - 24.3.1 BUSINESS OVERVIEW
 - 24.3.2 PRODUCT OFFERINGS
- 24.4 BTNX
 - 24.4.1 BUSINESS OVERVIEW
 - 24.4.2 PRODUCT OFFERINGS
- 24.5 CARDIOGENICS
 - 24.5.1 BUSINESS OVERVIEW
 - 24.5.2 PRODUCT OFFERINGS
- 24.6 CREATIVE DIAGNOSTICS
 - 24.6.1 BUSINESS OVERVIEW
 - 24.6.2 PRODUCT OFFERINGS
- 24.7 DIASORIN
 - 24.7.1 BUSINESS OVERVIEW
 - 24.7.2 PRODUCT OFFERINGS
- 24.8 LIFE DIAGNOSTICS
 - 24.8.1 BUSINESS OVERVIEW
 - 24.8.2 PRODUCT OFFERINGS
- 24.9 LUMIRADX
 - 24.9.1 BUSINESS OVERVIEW
 - 24.9.2 PRODUCT OFFERINGS
- 24.10 MEDIX BIOCHEMICA
 - 24.10.1 BUSINESS OVERVIEW
 - 24.10.2 PRODUCT OFFERINGS
- 24.11 MESO SCALE DIAGNOSTICS
 - 24.11.1 BUSINESS OVERVIEW
 - 24.11.2 PRODUCT OFFERINGS

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 24.12 MP BIOMAEDICALS
 - 24.12.1 BUSINESS OVERVIEW
 - 24.12.2 PRODUCT OFFERINGS
- 24.13 QUIDEL
 - 24.13.1 BUSINESS OVERVIEW
 - 24.13.2 PRODUCT OFFERINGS
- 24.14 RANDOX LABORATORIES
 - 24.14.1 BUSINESS OVERVIEW
 - 24.14.2 PRODUCT OFFERINGS
- 24.15 RESPONSE BIOMEDICAL
 - 24.15.1 BUSINESS OVERVIEW
 - 24.15.2 PRODUCT OFFERINGS
- 24.16 TOSOH
 - 24.16.1 BUSINESS OVERVIEW
 - 24.16.2 PRODUCT OFFERINGS

- 25 REPORT SUMMARY
 - 25.1 KEY TAKEAWAYS
 - 25.2 STRATEGIC RECOMMENDATIONS

- 26 QUANTITATIVE SUMMARY
 - 26.1 MARKET BY BIOMARKER TYPE
 - 26.1.1 NORTH AMERICA MARKET BY BIOMARKER TYPE
 - 26.1.2 EUROPE MARKET BY BIOMARKER TYPE
 - 26.1.3 APAC MARKET BY BIOMARKER TYPE
 - 26.1.4 LATIN AMERICA MARKET BY BIOMARKER TYPE
 - 26.1.5 MIDDLE EAST & AFRICA MARKET BY BIOMARKER TYPE
 - 26.2 MARKET BY APPLICATION
 - 26.2.1 NORTH AMERICA MARKET BY APPLICATION
 - 26.2.2 EUROPE MARKET BY APPLICATION
 - 26.2.3 APAC MARKET BY APPLICATION
 - 26.2.4 LATIN AMERICA MARKET BY APPLICATION
 - 26.2.5 MIDDLE EAST & AFRICA MARKET BY APPLICATION
 - 26.3 MARKET BY END-USER
 - 26.3.1 NORTH AMERICA MARKET BY END-USER
 - 26.3.2 EUROPE MARKET BY END-USER
 - 26.3.3 APAC MARKET BY END-USER
 - 26.3.4 LATIN AMERICA MARKET BY END-USER
 - 26.3.5 MIDDLE EAST & AFRICA MARKET BY END-USER
 - 26.4 MARKET BY GEOGRAPHY
 - 26.4.1 TROPONIN MARKET BY GEOGRAPHY
 - 26.4.2 CREATINE KINASE (CK-MB) MARKET BY GEOGRAPHY
 - 26.4.3 MYOGLOBIN MARKET BY GEOGRAPHY
 - 26.4.4 OTHER MARKET BY GEOGRAPHY
 - 26.4.5 ACUTE CORONARY SYNDROME MARKET BY GEOGRAPHY
 - 26.4.6 MYOCARDIAL INFRACTION MARKET BY GEOGRAPHY
 - 26.4.7 CONGESTIVE HEART FAILURE MARKET BY GEOGRAPHY

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

26.4.8 OTHERS MARKET BY GEOGRAPHY
26.4.9 HOSPITALS MARKET BY GEOGRAPHY
26.4.10 DIAGNOSTIC LABORATORIES MARKET BY GEOGRAPHY
26.4.11 OTHER MARKET BY GEOGRAPHY

27 APPENDIX

27.1 ABBREVIATIONS

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Cardiac Biomarkers Market - Global Outlook & Forecast 2023-2028

Market Report | 2023-10-20 | 305 pages | Arizton Advisory & Intelligence

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4200.00
	Team License	\$4999.00
	Enterprisewide	\$5999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-03"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com